Blog / Archives
Large Cap Biopharmaceutical Metrics: Valuation Models for Future Growth
Large Cap Biopharmaceutical Valuation Models Can Biotech Growth Re-accelerate in Q4? We reviewed large cap biotech stocks on July 3 just after the BREXIT bottom but prior to Q2 earnings and on May 8...
Biotech Breakout Part 2: Hold Your Fire…Update 8/15/16
Update August 15 : Biotech Leads But Healthcare Sector Lags IBB up 0.92% to $295, XBI up 1.33% to $63.35, XLV up 0.17% to $74.91 The tape was pretty decent despite a quiet day with ALXN up 1.97%,...
Biotech Breakout: Is the Bull Market Back?…Update-1 IBB,BMY
8/5 After the Close... NASDAQ Up 1.06% The IBB inched up 0.38% to $297.29 while the more volatile XBI did better up 1.07%. Both are still down YTD and trail the QQQ which is up 4.39% YTD. Investors...
Biotech Stocks Strike a Bullish Tone: BLUE, IBB, REGN, SGEN…Update-2
Bullish Tone-Large Cap Biopharmaceutical Earnings Updates 8/5 Regeneron (REGN) shares fell another 2.4% to $423 despite a jump of 23% on Eylea sales to $832M compared to $655 M in the prior-year...
Biotechs Get a Turbo Boost from Biogen(BIIB)…Update-1 GILD
Update-1... Gilead Sciences (GILD) Sells Off on earnings Gilead Sciences (GILD) sold off over 4% after hours after releasing second quarter sales of $7.7B and earnings of $3.08/sh. Q2 profit...
Biotech Bear Market Rally: Can Active Funds Beat the ETFs?
Biotech Bear Market Rally Headed Toward Triple Top The biotech rally has wobbly legs moving briskly from the Brexit lows but with choppy action recently.This would be the third time biotech stocks...
Biotech Rally Up 8% from Brexit Bottom: Rayno Biopharmaceutical Portfolio Update: July 11, 2016…Update-1
Update-1... 7/12/16 Dow and S&P Hit Record Highs, Awaiting Q2 Earnings-Risk Still On-Biotech Stocks Lag The market continued its post-BREXIT rally helped by low interest rates and WTI crude up...
Foundation Medicine (FMI): New Pick Added To Raygent Core Portfolio
Foundation Medicine (FMI) New Pick at $20.40 We have added Foundation Medicine (FMI) to our core portfolio because of their leadership position in pharmacogenomics and molecular medicine for cancer...
Large Cap Biopharmaceuticals-Valuation Models 2016
Biopharmaceutical Valuations Look Attractive Sector Poised for Rebound by Year End This is a continuing review of large cap biopharmaceutical valuation metrics to determine which companies can...
BRexit Bottom for Biotech Creates Buying Opportunity…Update-2
Update-2 ...6/30 after the close Biotech stocks rallied again for the third day but momentum ebbed. Large caps were mainly in the green led by Alexion Pharmaceuticals (ALXN), Roche Holding (RHHBY)...